[New biopsy at lung cancer progression: rational treatment of resistant lung cancer]. / Opnieuw biopteren bij progressie van longkanker.
Ned Tijdschr Geneeskd
; 161: D1229, 2017.
Article
em Nl
| MEDLINE
| ID: mdl-28558851
ABSTRACT
Nowadays, patients with advanced non-small cell lung cancer harbouring a driver mutation undergo targeted treatment. This results in profound tumour responses but inevitably induces resistance after approximately 9 to 12 months. In this article we consider the importance and clinical implications of taking new biopsies to retrieve information regarding resistance mechanisms. There is a shift in the use of other modalities such as radiotherapy and surgery in patients with oligometastatic disease, producing long-lasting responses. This is illustrated by three different patient cases one with an EGFR exon 21 mutation, obtaining a T790M mutation upon treatment; another with a BRAF V600 mutation initially treated with chemotherapy and later with targeted therapy; and, finally, a patient with an ALK translocation with progression on crizotinib treatment, responding to subsequent alectinib therapy. The latter developed oligometastatic disease that was treated with radiotherapy, resulting in a complete response for at least 2 years.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Biópsia
/
Carcinoma Pulmonar de Células não Pequenas
/
Resistencia a Medicamentos Antineoplásicos
/
Neoplasias Pulmonares
Tipo de estudo:
Prognostic_studies
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
Nl
Revista:
Ned Tijdschr Geneeskd
Ano de publicação:
2017
Tipo de documento:
Article